Adams S, Loi S, Toppmeyer D, et al. Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B. J Clin Oncol. 2017;35. Abstract 1088.
Cortés J, Guo Z, Karantza V, et al. KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (PBO) + chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC). J Clin Oncol. 2018;36. Abstract TPS18.
Cortés J, Lipatov O, Im SA, et al. KEYNOTE-119: Phase 3 study of pembrolizumab versus single-agent chemotherapy for metastatic triple-negative breast cancer. ESMO 2019. Abstract LBA21.
Emens LA, Loi S, Rugo H, et al. IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer. Cancer Res. 2019;79. Abstract GS1-04.
Nanda R, Liu MC, Yau C, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. J Clin Oncol. 2017;35. Abstract 506.
Rugo HS, Loi S, Adams S, et al. Performance of PD-L1 immunohistochemistry assays in unresectable locally advanced or metastatic triple negative breast cancer: Post hoc analysis of IMpassion130. ESMO 2019. Abstract LBA20.
Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108-2121.
Schmid P, Adams S, Rugo H, et al. IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC). Ann Oncol. 2018;29. Abstract LBA1.
Schmid P, Adams S, Rugo HS, et al. IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). J Clin Oncol. 2019;37. Abstract 1003.
Schmid P, Cortés J, Dent R, et al. KEYNOTE-522: Phase 3 study of pembrolizumab + chemotherapy versus placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab versus placebo as adjuvant treatment for early triple-negative breast cancer (TNBC). ESMO 2019. Abstract LBA8.
Schmid P, Cruz C, Braiteh FS, et al. Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses. Cancer Res. 2017;77. Abstract 2986.
Schmid P, Loirat D, Espinosa E, et al. Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC) Cancer Res. 2019;79. Abstract CT049.
Schmid P, Park YH, Muñoz-Couselo E, et al. Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173. J Clin Oncol. 2017;35. Abstract 556.
Thill M, Jackisch C, Janni W, et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. Breast Care (Basel). 2019;14:247-255.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Peter Schmid, MD, PhD, FRCP

Lead, Centre for Experimental Cancer Medicine
Barts Cancer Institute, St Bartholomew’s Hospital
Queen Mary University of London
London, United Kingdom

Disclosures

Disclosure: Peter Schmid, MD, PhD, FRCP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Eisai Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Puma; Roche
Received grants for clinical research from: Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Oncogenex; Roche
Other: Spouse: Genentech, Inc.; Roche

Editor

Charlotte Warren

Senior Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Charlotte Warren has disclosed no relevant financial relationships.

Zach Hartman, PhD

Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Zach Hartman, PhD has disclosed no relevant financial relationships.

CME Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC

Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer: What Should You Know?

Authors: Peter Schmid, MD, PhD, FRCP
CME / ABIM MOC Released: 11/12/2019
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 11/12/2020

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of oncologists, obstetricians & gynecologists, and surgeons.

The goal of this activity is to increase understanding of the use of checkpoint inhibition in triple-negative breast cancer (TNBC) in the metastatic and neoadjuvant settings.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Clinical trials studying the use of immune checkpoint inhibitors in patients with TNBC in the neoadjuvant and metastatic settings
- How to identify which patients with TNBC may benefit from use of immune checkpoint inhibitors

Disclosures

Faculty

Peter Schmid, MD, PhD, FRCP

Lead, Centre for Experimental Cancer Medicine
Barts Cancer Institute, St Bartholomew’s Hospital
Queen Mary University of London
London, United Kingdom

Disclosures

Disclosure: Peter Schmid, MD, PhD, FRCP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Eisai Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Puma; Roche
Received grants for clinical research from: Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Oncogenex; Roche
Other: Spouse: Genentech, Inc.; Roche

Editor

Charlotte Warren

Senior Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Charlotte Warren has disclosed no relevant financial relationships.

Zach Hartman, PhD

Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Zach Hartman, PhD has disclosed no relevant financial relationships.

CME Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

processing....

Educational Impact Challenge

What did you learn from this activity? Please answer the following question.

« Back

Page 2 of 4

Educational Impact Challenge

CME / ABIM MOC Information Download Slides

Print
Like Tweet

References

Faculty and Disclosures

Faculty

Peter Schmid, MD, PhD, FRCP

Editor

Charlotte Warren

Zach Hartman, PhD

CME Reviewer

Robert Morris, PharmD

CME / ABIM MOC

Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer: What Should You Know?

Target Audience and Goal Statement

Disclosures

Faculty

Peter Schmid, MD, PhD, FRCP

Editor

Charlotte Warren

Zach Hartman, PhD

CME Reviewer

Robert Morris, PharmD

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer: What Should You Know?

Educational Impact Challenge